Oxagen Limited is a privately-held biopharmaceutical company working in collaboration with Eleventa LLC to develop and commercialise OC000459 for the Russian and CIS markets.
OC000459 is a once-daily oral CRTH2 antagonist which has demonstrated encouraging activity in the treatment of eosinophilic asthma and allergic rhinoconjunctivitis, and an excellent safety profile.
Eleventa LLC, part of the Russian biotech holding company OOO Maxwell Biotech Group, has exclusive rights to commercialise OC000459 in Russia and CIS, and is planning to conduct a pivotal clinical trial to obtain drug approval from the Russian regulatory authorities and launch OC000459 into the Russian asthma market.
The rights to exploit OC000459 and back-up molecules worldwide excluding Russia and CIS, were assigned by Oxagen to Atopix Therapeutics Limited in October 2012.
Oxagen owns, and will actively enforce and defend, intellectual property rights relating to OC000459. Except for Atopix Therapeutics Limited and nominated sub-contractors, no company other than Oxagen has any rights to manufacture, market, use or sell OC000459, anywhere in the world.
Oxagen has no data at all, either pre-clinical or clinical, to support the therapeutic use of OC000459 in male-pattern baldness.